<VariationArchive RecordType="classified" VariationID="10986" VariationName="OTC, DEL" VariationType="Deletion" Accession="VCV000010986" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2023-03-26" DateCreated="2013-04-04" MostRecentSubmission="2013-04-04">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26025" VariationID="10986">
      <GeneList>
        <Gene Symbol="OTC" FullName="ornithine transcarbamylase" GeneID="5009" HGNC_ID="HGNC:8512" Source="submitted" RelationshipType="asserted, but not computed">
          <Location>
            <CytogeneticLocation>Xp11.4</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="38327684" stop="38422928" display_start="38327684" display_stop="38422928" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="38211735" stop="38280702" display_start="38211735" display_stop="38280702" Strand="+" />
          </Location>
          <OMIM>300461</OMIM>
          <Haploinsufficiency last_evaluated="2012-06-28" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=OTC">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2012-06-28" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=OTC">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>OTC, DEL</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>Xp21.1</CytogeneticLocation>
      </Location>
      <OtherNameList>
        <Name>OTC, DEL</Name>
        <Name>DEL</Name>
      </OtherNameList>
      <XRefList>
        <XRef Type="Allelic variant" ID="300461.0001" DB="OMIM" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff could not determine the sequence change on a current reference sequence after review of PubMed 2843770.</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="OTC, DEL AND Ornithine carbamoyltransferase deficiency" Accession="RCV000011733" Version="9">
        <ClassifiedConditionList TraitSetID="3053">
          <ClassifiedCondition DB="MedGen" ID="C0268542">Ornithine carbamoyltransferase deficiency</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1990-08-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1990-08-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2013-04-04" MostRecentSubmission="2013-04-04">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">2208768</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2843770</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3053" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="3120" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Ornithine Carbamoyltransferase Deficiency Disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Ornithine carbamoyltransferase deficiency</ElementValue>
                <XRef ID="Ornithine+transcarbamylase+deficiency/5412" DB="Genetic Alliance" />
                <XRef ID="MONDO:0010703" DB="MONDO" />
                <XRef ID="80908008" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">OTC deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Ornithine transcarbamylase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">ORNITHINE TRANSCARBAMYLASE DEFICIENCY, HYPERAMMONEMIA DUE TO</ElementValue>
                <XRef Type="MIM" ID="311250" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">OTCD</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="8391" />
                <XRef ID="8391" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Ornithine transcarbamylase (OTC) deficiency can occur as a severe neonatal-onset disease in males (but rarely in females) and as a post-neonatal-onset (also known as "late-onset" or partial deficiency) disease in males and females. Males with severe neonatal-onset OTC deficiency are asymptomatic at birth but become symptomatic from hyperammonemia in the first week of life, most often on day two to three of life, and are usually catastrophically ill by the time they come to medical attention. After successful treatment of neonatal hyperammonemic coma these infants can easily become hyperammonemic again despite appropriate treatment; they typically require liver transplant to improve quality of life. Males and heterozygous females with post-neonatal-onset (partial) OTC deficiency can present from infancy to later childhood, adolescence, or adulthood. No matter how mild the disease, a hyperammonemic crisis can be precipitated by stressors and become a life-threatening event at any age and in any situation in life. For all individuals with OTC deficiency, typical neuropsychological complications include developmental delay, learning disabilities, intellectual disability, attention-deficit/hyperactivity disorder, and executive function deficits.</Attribute>
                <XRef ID="NBK154378" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301396</ID>
                <ID Source="BookShelf">NBK1217</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24006547</ID>
                <ID Source="BookShelf">NBK154378</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Decreased-Citrulline.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Newborn Screening ACT Sheet, Decreased Citrulline, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Decreased-Citrulline-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Decreased Citrulline, 2022</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2012">
                <URL>https://www.acmg.net/PDFLibrary/OTC-Deficiency-Transition.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Transition to Adult Health Care ACT Sheet, Ornithine Transcarbamylase (OTC) deficiency, 2012</CitationText>
              </Citation>
              <XRef ID="664" DB="Orphanet" />
              <XRef ID="C0268542" DB="MedGen" />
              <XRef ID="MONDO:0010703" DB="MONDO" />
              <XRef Type="MIM" ID="311250" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="31965" SubmissionDate="2006-10-13" DateLastUpdated="2013-04-04" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300461.0001_ORNITHINE TRANSCARBAMYLASE DEFICIENCY" title="OTC, DEL_ORNITHINE TRANSCARBAMYLASE DEFICIENCY" />
        <ClinVarAccession Accession="SCV000031965" DateUpdated="2013-04-04" DateCreated="2013-04-04" Type="SCV" Version="1" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1990-08-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Maddalena et al. (1988) found somatic mosaicism for an intragenic deletion of the OTC gene in a boy with mild OTC deficiency (311250) who had a history of only 1 hospitalization for hyperammonemia and no evidence of neurologic injury at 6 years of age. In a boy in whom mild OTC deficiency was first diagnosed at the age of 8 months, Legius et al. (1990) also found somatic mosaicism for a deletion in the OTC gene.</Attribute>
              <Citation>
                <ID Source="PubMed">2843770</ID>
              </Citation>
              <Citation>
                <ID Source="PubMed">2208768</ID>
              </Citation>
              <XRef DB="OMIM" ID="311250" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="OTC" />
          </GeneList>
          <Name>OTC, DEL</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">DEL</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300461.0001" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">ORNITHINE TRANSCARBAMYLASE DEFICIENCY</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="31965" TraitType="Disease" MappingType="Name" MappingValue="ORNITHINE TRANSCARBAMYLASE DEFICIENCY" MappingRef="Preferred">
        <MedGen CUI="C0268542" Name="Ornithine carbamoyltransferase deficiency" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

